Group 1 - Altria is recognized as a top stock for investors seeking high yield while protecting capital, particularly due to its focus on the U.S. market since its 2008 spinoff from Philip Morris International [1] - The company is transitioning from traditional cigarettes to smoke-free products, including vapes and nicotine pouches, indicating a strategic pivot in its product offerings [1] - Altria's stock has shown improved price performance, earning upgrades in its Relative Strength Rating, reflecting positive market sentiment [3] Group 2 - Altria's stock offers a dividend yield of 7.1%, positioning it as a competitive option among high-yield stocks [3] - The company has successfully mitigated tariff risks associated with its products, enhancing its market stability [3] - Altria has joined an elite group of stocks with Relative Strength Ratings over 90, showcasing its strong market performance [3]

NORWOOD, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- InHouse™ announced today the launch of its second annual Help on the Homefront campaign, a philanthropic effort that provides veterans the chance to win funds to help offset their cost of housing or home improvements. Help on the Homefront debuted in 2024 to raise awareness of the nationwide issue of veteran housing challenges and homelessness. InHouse, a line of cannabis high quality flower, vapes, and gummies, is produced and distributed by leading multi-s ...

Local Veterans in Maryland, Massachusetts, Delaware, and Illinois Can Enter to Win $5,000 to Help Offset the Cost of Housing or Home Improvements through November 30NORWOOD, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- InHouse™ announced today the launch of its second annual Help on the Homefront campaign, a philanthropic effort that provides veterans the chance to win funds to help offset their cost of housing or home improvements. Help on the Homefront debuted in 2024 to raise awareness of the nationwide issu ...

CANADA - 2025/07/28: In this photo illustration, the Tilray Brands logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesTilray Brands (NASDAQ: TLRY) has witnessed a considerable surge, rising nearly 200% from $0.42 in early July to its present price of $1.24. This increase is largely attributed to the Trump administration's deliberation on reclassifying cannabis from a Schedule I to a Schedule III ...

Cannara Biotech Conference Summary Company Overview - **Company Name**: Cannara Biotech Inc. - **Stock Symbol**: LOVE (TSXV) - **Industry**: Canadian Cannabis - **Founded**: 2018 - **Headquarters**: Quebec, Canada - **Facilities**: Operates over 1.6 million square feet across two fully owned facilities in Quebec [2][5] Core Business and Market Position - Cannara Biotech is a vertically integrated cannabis company focused on producing premium-grade cannabis at scale, emphasizing profitability, innovation, and long-term value creation [2][4] - Currently the **seventh largest producer** in Canada by sales and **second largest** in Quebec, with a **12.8% market share** in Quebec, up from 9.7% a year ago [5][17] - Annualized production run rate is approximately **50,000 kilograms** (50 million grams) [5][6] Financial Performance - **Q3 2025**: Best quarterly financial results in the company's history - **Nine months of 2025**: - Net revenue: **$80 million** - Gross profit: **$32.7 million** - Gross margin: **41%**, with steady quarter-over-quarter increases [9][10] - Adjusted EBITDA: **$20.7 million** (26% of revenues) [10] - Net income: **$9.8 million**, a **53% increase** from the previous year [10] - **Cash Flow**: Generated **$17.2 million** in operating cash flow and **$12.3 million** in free cash flow in the first nine months of 2025 [11] Operational Highlights - Achieved a **26% increase** in capacity over the past year without additional capital costs [6][9] - Vertical integration allows full control over the cannabis supply chain, enhancing quality and efficiency [7][24] - Upcoming launch of a new vape category in Quebec, with **20% retail shelf space** already secured [8][17] Competitive Advantages - Strong operational platform with a focus on premium quality, scalable operations, and cost leadership [8][9] - Access to Quebec's low electricity rates of **$0.059 per kilowatt**, significantly lower than other provinces [26] - High barriers to entry in Quebec due to strict regulations on sales and marketing, allowing Cannara to thrive without heavy promotional activities [26][27] Strategic Initiatives - Plans for a **$10 million investment** in a new dedicated processing center to support growth and expand capacity to **100,000 kilograms** annually [16][24] - Focus on internal growth rather than external acquisitions, emphasizing operational discipline and quality [25][27] Market Trends and Outlook - The Canadian cannabis market is experiencing a shift, with a **41% surge** in estimated retail sales year-over-year, positioning Cannara as a leader in growth [16][17] - The company is well-prepared to meet unserved demand and capitalize on upcoming market opportunities, particularly in the vape segment [8][17] Conclusion - Cannara Biotech is positioned as a dominant player in the Canadian cannabis market, with a strong financial performance, operational efficiencies, and a clear growth strategy focused on quality and innovation [2][9][27]

Core Viewpoint - Canopy Growth Corporation has launched a new at-the-market equity program to raise up to $200 million in common shares, aimed at supporting strategic investments and working capital [1][2]. Group 1: Equity Program Details - The new equity program allows for the issuance and sale of up to $200 million in common shares across U.S. and Canadian markets, with Canadian sales capped at $50 million [2]. - The program is governed by an equity distribution agreement dated August 29, 2025, with BMO Nesbitt Burns Inc. and BMO Capital Markets Corp. as agents [3]. - The program will remain active until June 5, 2027, or until the full $200 million is raised, with the Canadian portion ending earlier on July 5, 2026, or upon reaching its $50 million cap [3]. Group 2: Company Overview - Canopy Growth Corporation operates in the cannabis industry, producing and selling cannabis, hemp, and related products across Canada, Germany, and Australia [4]. - The company operates through four segments, including Canada Cannabis and International Markets, offering a variety of products such as dried flower, pre-rolls, edibles, vapes, oils, and concentrates [4]. - Canopy Growth markets its products under multiple brands, including Tweed, 7ACRES, Spectrum Therapeutics, Storz & Bickel, Wana, and DOJA [4].

This story was originally published on C-Store Dive. To receive daily news and insights, subscribe to our free daily C-Store Dive newsletter. Dive Brief: 7-Eleven will pay $1.2 million to resolve charges that it violated a Washington, D.C., restriction on where vapes and e-cigarettes can be sold, the Office of the Attorney General for the District of Columbia announced on Tuesday. A D.C. law enacted in October 2022 prohibits such devices from being sold within a quarter mile of middle and high schools ...

Earlier today, pursuant to search warrants issued by federal courts, US Marshalss began seizing hundreds of thousands of units of illicit vaping products at locations across the United States. Many of these products were smuggled in from China, circumventing regulations. They often contain undisclosed or untested chemicals which fail to meet FDA safety standards.of these kind of operations we're doing to to target the biggest distributors but also to send a message throughout this entire industry that this ...

Core Insights - Nextleaf Solutions Ltd. reported its financial results for Q3 FY2025, achieving gross revenue of $3,769,797, net revenue of $2,912,572, and gross profit of $1,107,593, marking the fourth consecutive profitable quarter without normalization [1][6]. Financial Performance - The gross profit increased by 25% from $884,344 in the same period last year, maintaining a steady gross margin of 29% [6]. - Year-to-date net income reached $867,352, a significant improvement of 172% from a loss of $1,196,316 in FY24 [6]. - Positive EBITDA of $1,112,285 year-to-date highlights the company's operational efficiency and disciplined cost management [6]. Market Position and Strategy - The company has streamlined its product portfolio and enhanced competitiveness through targeted SKU rationalization, strategic pricing, and brand innovation [2]. - Despite competitive pressure in saturated categories, Nextleaf remains on track to exceed FY24 revenue, net income, and adjusted EBITDA targets, driven by leadership in wellness-forward formats like softgels and oils [3]. Product Development and Launches - Nextleaf launched 11 new products under its flagship brand Glacial Gold, including 3 softgels, 5 vapes, and 3 bottled oils, with national distribution [4]. - The company focuses on delivering standardized, consistent, dose-controlled extracts with high potency and purity, appealing to wellness-focused adult-use consumers [4]. Financial Health - The company ended the quarter with no secured debt, a debt-to-equity ratio of 0.61, and strong shareholder equity of $5.6 million, indicating disciplined financial management [3][7]. - Working capital improved by 24% compared to year-end September 30, 2024, closing at $5,601,524 [7]. Future Outlook - The company plans to prioritize working capital allocation to strategic initiatives in Q4 FY2025, including scaling softgel innovation and advancing consumer value in vapes [9][13].

Industry Overview - The Canadian cannabis sector is gaining investor attention as the U.S. market approaches broader reform, with the U.S. cannabis market projected to reach approximately $38.5 billion in 2024 and grow at a CAGR of 11-12% through the late 2020s [1][3] - Legislative changes in the U.S., such as Delaware's adult-use cannabis sales starting August 1, 2025, and potential federal rescheduling of marijuana, are creating strong thematic tailwinds for Canadian cannabis stocks with U.S. exposure [1][3] Company Highlights Tilray Brands (TLRY) - Tilray has established a strong global identity by combining cannabis, wellness, and beverages, significantly expanding its U.S. footprint through acquisitions [4][6] - The company reported record revenue exceeding $820 million for fiscal 2025, with gross margins averaging around 40%, showcasing strong cost management [8][9] - Tilray's strategic pivot into hemp-based beverages and wellness products allows it to build a presence in the U.S. market despite federal restrictions [10][7] Canopy Growth Corporation (CGC) - Canopy Growth is recognized as a leading cannabis company in Canada, with ambitions to enter the U.S. market through strategic partnerships and acquisitions, notably its option to acquire Acreage Holdings [10][12] - The company generated nearly $300 million in revenue but reported a net loss exceeding $650 million, highlighting ongoing profitability challenges [14][15] - Canopy's U.S. strategy is designed to unlock value upon legalization, with a strong brand portfolio and rights to Acreage Holdings representing potential growth [16] Village Farms International (VFF) - Village Farms operates in both agriculture and cannabis, leveraging its expertise in greenhouse cultivation to strengthen its cannabis operations in Canada [18][19] - The company reported net income above $25 million in 2025, with adjusted EBITDA reaching nearly 30% of total sales, demonstrating strong profitability and revenue growth [20] - Village Farms' focus on cultivation efficiency and vertical integration has allowed it to achieve profitability, distinguishing it from many cannabis peers [20][21] Conclusion - Tilray, Canopy Growth, and Village Farms each demonstrate unique strategies for growth and financial improvement in the evolving cannabis landscape [21] - These companies are well-positioned to capitalize on potential U.S. legalization and changing market dynamics, offering various investment opportunities [21]